RS55945B1 - Nova so 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidin-2,4-diona, njena izrada, kao i formulacije koje je sadrže - Google Patents

Nova so 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidin-2,4-diona, njena izrada, kao i formulacije koje je sadrže

Info

Publication number
RS55945B1
RS55945B1 RS20170461A RSP20170461A RS55945B1 RS 55945 B1 RS55945 B1 RS 55945B1 RS 20170461 A RS20170461 A RS 20170461A RS P20170461 A RSP20170461 A RS P20170461A RS 55945 B1 RS55945 B1 RS 55945B1
Authority
RS
Serbia
Prior art keywords
morpholinylmethyl
thiazolidine
pyrrol
indol
dione
Prior art date
Application number
RS20170461A
Other languages
English (en)
Inventor
Flohic Alexandre Le
Jérôme Guidotti
Philippe Letellier
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of RS55945B1 publication Critical patent/RS55945B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20170461A 2013-07-12 2014-07-11 Nova so 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidin-2,4-diona, njena izrada, kao i formulacije koje je sadrže RS55945B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
EP14758600.2A EP3019497B1 (fr) 2013-07-12 2014-07-11 Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent
PCT/FR2014/051783 WO2015004395A1 (fr) 2013-07-12 2014-07-11 Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent

Publications (1)

Publication Number Publication Date
RS55945B1 true RS55945B1 (sr) 2017-09-29

Family

ID=50424327

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170461A RS55945B1 (sr) 2013-07-12 2014-07-11 Nova so 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidin-2,4-diona, njena izrada, kao i formulacije koje je sadrže

Country Status (47)

Country Link
US (2) US9925195B2 (sr)
EP (1) EP3019497B1 (sr)
JP (1) JP6532459B2 (sr)
KR (2) KR20160030399A (sr)
CN (1) CN105377843B (sr)
AP (1) AP2016008976A0 (sr)
AR (1) AR096882A1 (sr)
AU (1) AU2014289059B2 (sr)
CA (1) CA2916380C (sr)
CL (1) CL2016000013A1 (sr)
CR (1) CR20160012A (sr)
CU (1) CU20160005A7 (sr)
CY (1) CY1119259T1 (sr)
DK (1) DK3019497T3 (sr)
DO (1) DOP2016000005A (sr)
EA (1) EA031526B1 (sr)
ES (1) ES2632570T3 (sr)
FR (1) FR3008411B1 (sr)
GE (1) GEP201706712B (sr)
GT (1) GT201600004A (sr)
HK (2) HK1222172A1 (sr)
HR (1) HRP20171060T1 (sr)
HU (1) HUE032568T2 (sr)
IL (1) IL243526B (sr)
JO (1) JO3292B1 (sr)
LT (1) LT3019497T (sr)
MA (1) MA38759B1 (sr)
MD (1) MD4507C1 (sr)
ME (1) ME02735B (sr)
MX (1) MX360291B (sr)
MY (1) MY183197A (sr)
NI (1) NI201600009A (sr)
NZ (1) NZ715841A (sr)
PE (1) PE20160079A1 (sr)
PH (1) PH12016500017A1 (sr)
PL (1) PL3019497T3 (sr)
PT (1) PT3019497T (sr)
RS (1) RS55945B1 (sr)
RU (1) RU2680826C9 (sr)
SA (1) SA516370388B1 (sr)
SG (1) SG11201510570YA (sr)
SI (1) SI3019497T1 (sr)
TN (1) TN2015000566A1 (sr)
TW (2) TWI554510B (sr)
UA (1) UA114041C2 (sr)
UY (1) UY35629A (sr)
WO (1) WO2015004395A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
EP1328519B1 (en) * 2000-10-17 2005-09-07 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE60205776T2 (de) * 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
EP1680401A2 (en) * 2003-10-24 2006-07-19 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
ES2391575T3 (es) * 2005-12-05 2012-11-27 Xenoport, Inc. Mesilato de profármaco de Levodopa, sus composiciones y sus usos
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12016500017B1 (en) 2016-04-18
JP6532459B2 (ja) 2019-06-19
US20160151378A1 (en) 2016-06-02
AU2014289059A1 (en) 2016-02-04
EP3019497A1 (fr) 2016-05-18
CU20160005A7 (es) 2016-05-30
RU2680826C2 (ru) 2019-02-28
HK1222655A1 (zh) 2017-07-07
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
TN2015000566A1 (fr) 2017-04-06
JP2016523953A (ja) 2016-08-12
UY35629A (es) 2015-01-30
GT201600004A (es) 2018-09-28
DK3019497T3 (en) 2017-08-07
MD4507B1 (ro) 2017-08-31
MD20160003A2 (ro) 2016-06-30
HRP20171060T1 (hr) 2017-10-06
FR3008411B1 (fr) 2015-07-03
MA38759A1 (fr) 2018-01-31
CL2016000013A1 (es) 2016-08-12
SA516370388B1 (ar) 2017-12-14
LT3019497T (lt) 2017-05-25
AP2016008976A0 (en) 2016-01-31
EA201600101A1 (ru) 2016-06-30
SI3019497T1 (sl) 2017-07-31
CA2916380C (fr) 2017-11-21
MX2016000332A (es) 2016-05-09
US9925195B2 (en) 2018-03-27
DOP2016000005A (es) 2016-12-15
MD4507C1 (ro) 2018-03-31
CN105377843B (zh) 2019-03-05
MX360291B (es) 2018-10-29
MA38759B1 (fr) 2018-09-28
ES2632570T3 (es) 2017-09-14
KR20160030399A (ko) 2016-03-17
UA114041C2 (xx) 2017-04-10
IL243526B (en) 2019-09-26
JO3292B1 (ar) 2018-09-16
CN105377843A (zh) 2016-03-02
TW201504236A (zh) 2015-02-01
PT3019497T (pt) 2017-05-15
WO2015004395A1 (fr) 2015-01-15
NI201600009A (es) 2016-02-11
TW201630906A (zh) 2016-09-01
PL3019497T3 (pl) 2017-09-29
CA2916380A1 (fr) 2015-01-15
HK1222172A1 (zh) 2017-06-23
FR3008411A1 (fr) 2015-01-16
RU2680826C9 (ru) 2019-03-01
MY183197A (en) 2021-02-18
CY1119259T1 (el) 2018-02-14
EP3019497B1 (fr) 2017-04-12
TWI554510B (zh) 2016-10-21
NZ715841A (en) 2019-04-26
AR096882A1 (es) 2016-02-03
AU2014289059B2 (en) 2017-05-25
ME02735B (me) 2017-10-20
IL243526A0 (en) 2016-02-29
PE20160079A1 (es) 2016-02-06
SG11201510570YA (en) 2016-01-28
RU2016104642A (ru) 2017-08-17
PH12016500017A1 (en) 2016-04-18
HUE032568T2 (hu) 2017-09-28
GEP201706712B (en) 2017-07-25
US20180207171A1 (en) 2018-07-26
KR20180028554A (ko) 2018-03-16

Similar Documents

Publication Publication Date Title
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
HK1225731B (zh) (s)-(2-(6-氯-7-甲基-1h-苯並[d]咪唑-2-基)-2-甲基吡咯啶-1-基)(5-甲氧基-2-(2h-1，2，3-三唑-2-基)苯基)甲酮的晶形及其作為食欲素受體拮抗劑的用途
SG11201507336WA (en) Solid forms of 5-(halomethyl) furfural and methods for preparing thereof
IL243526B (en) A new salt of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-3,2-dihydro-1h-indol-5-yl)methyl] -3,1-thiazolidine-4,2-dione, its preparation and compositions containing it
HRP20180760T1 (hr) Kombinacija između 3-[(3-{[4-(4-morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona i egfr tir-kinaze inhibitora
TH1601000138A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
IL224486B (en) History of 2-phenyl-1-[4-(2-thiazolyl)-1-piperidinyl]ethanone as a fungicide